Mechanisms of IVIG Action in Immune Thrombocytopenic Purpura
Hansen, R.J.; Balthasar, J.P.
Clinical Laboratory 50(3-4): 133-140
2004
ISSN/ISBN: 1433-6510 PMID: 15074465 Document Number: 9328
Intravenous immunoglobulin (IVIG) has been an important therapy of immune thrombocytopenic purpura (ITP) for more than 20 years; however, questions still remain regarding the mechanisms of IVIG action in ITP. Recent reviews have focused on the hypotheses that IVIG effects are mediated via inhibition of Fc-receptor mediated platelet phagocytosis, suppression of anti-platelet antibody production, and anti-idiotypic inhibition of anti-platelet antibodies; however, new research suggests that a significant portion of IVIG benefit may be due to IVIGmediated acceleration of the elimination of anti-platelet antibodies. It is anticipated that promising new therapies of ITP, and other autoimmune conditions, will be developed based on a better understanding of IVIG mechanism of action.
Document emailed within 1 workday
